Markers of Cardiovascular Risk in Patients With Premature Coronary Artery Disease and Treatment

NCT04613167 · clinicaltrials.gov ↗

NA

Phase

UNKNOWN

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Acute Coronary Syndrome
Premature Coronary Heart Disease
Lipoproteinemia
Inflammation
Genetic Polymorphisms

Interventions

DRUG: Alirocumab
DRUG: Evolocumab
DRUG: Control group

Sponsor

University Medical Centre Ljubljana